Whooping cough vaccine in pregnancy: new study looks at how antibodies pass to babies
NCT ID NCT05856396
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at 200 women and their infants to understand how the whooping cough vaccine given during pregnancy affects the baby's immune protection. Researchers measured antibody levels in mothers and in umbilical cord blood at birth, as well as in infants after their own vaccines. The goal is to identify factors that influence how well protective antibodies are transferred from mother to child, which could improve vaccination strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pertussis-containing vaccines (Triaxis® and Vaxelis®)
What this could lead to
If successful, this could help design better vaccination schedules for pregnant women to protect newborns from whooping cough.
What could go wrong
This is an observational analysis of an already completed study, not a test of a new treatment. Results may not lead to immediate changes in practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VACCINATION; INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Saint-Pierre
Brussels, 1000, Belgium